Literature DB >> 27867609

Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial".

Ivana Sullivan1, David Planchard1.   

Abstract

Entities:  

Year:  2016        PMID： 27867609      PMCID： PMC5107501          DOI： 10.21037/jtd.2016.10.57

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

2.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Authors:  Luc Friboulet; Nanxin Li; Ryohei Katayama; Christian C Lee; Justin F Gainor; Adam S Crystal; Pierre-Yves Michellys; Mark M Awad; Noriko Yanagitani; Sungjoon Kim; AnneMarie C Pferdekamper; Jie Li; Shailaja Kasibhatla; Frank Sun; Xiuying Sun; Su Hua; Peter McNamara; Sidra Mahmood; Elizabeth L Lockerman; Naoya Fujita; Makoto Nishio; Jennifer L Harris; Alice T Shaw; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2014-03-27       Impact factor: 39.397

3.  Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

Authors:  Tsuyoshi Takahashi; Makoto Sonobe; Masashi Kobayashi; Akihiko Yoshizawa; Toshi Menju; Ei Nakayama; Nobuya Mino; Shotaro Iwakiri; Kiyoshi Sato; Ryo Miyahara; Kenichi Okubo; Toshiaki Manabe; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

4.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Authors:  Sai-Hong Ignatius Ou; Eunice L Kwak; Christina Siwak-Tapp; Joni Dy; Kristin Bergethon; Jeffrey W Clark; D Ross Camidge; Benjamin J Solomon; Robert G Maki; Yung-Jue Bang; Dong-Wan Kim; James Christensen; Weiwei Tan; Keith D Wilner; Ravi Salgia; A John Iafrate
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

5.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Authors:  Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

6.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Authors:  Takaaki Sasaki; Jussi Koivunen; Atsuko Ogino; Masahiko Yanagita; Sarah Nikiforow; Wei Zheng; Christopher Lathan; J Paul Marcoux; Jinyan Du; Katsuhiro Okuda; Marzia Capelletti; Takeshi Shimamura; Dalia Ercan; Magda Stumpfova; Yun Xiao; Stanislawa Weremowicz; Mohit Butaney; Stephanie Heon; Keith Wilner; James G Christensen; Michel J Eck; Kwok-Kin Wong; Neal Lindeman; Nathanael S Gray; Scott J Rodig; Pasi A Jänne
Journal:  Cancer Res       Date:  2011-07-26       Impact factor: 12.701

7.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

8.  Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

Authors:  Sai-Hong Ignatius Ou; Michele Azada; David J Hsiang; June M Herman; Tatiana S Kain; Christina Siwak-Tapp; Cameron Casey; Jie He; Siraj M Ali; Samuel J Klempner; Vincent A Miller
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.